COMMITMENTS AND CONTINGENCIES (Details 2) - USD ($)	1 Months Ended
	Aug. 31, 2014	Dec. 31, 2015	Oct. 31, 2015	Apr. 30, 2015	Mar. 31, 2010
Other commitments
Capital expenditures		$ 90,000,000
Milestone payments in terms of collaboration and license agreements, aggregate		1,500,000,000
Potential milestone payments in terms of collaboration and license agreements	$ 100,000,000
Milestone payment period (years)	5 years
Salix
Other commitments
Potential milestone payments in terms of collaboration and license agreements				$ 500,000,000
Possible contingent consideration		650,000,000
B&L and Nicox
Other commitments
Potential milestone payments in terms of collaboration and license agreements					$ 163,000,000
Pre-launch Milestone Payments | Brodalumab
Other commitments
Possible contingent consideration		170,000,000	$ 170,000,000
Sales Based Milestone Payments | Brodalumab
Other commitments
Possible contingent consideration		$ 175,000,000	$ 175,000,000